A randomized phase II study of Fulvestrant in combination with the dual mTOR inhibitor AZD2014 or Everolimus or Fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer
Peter Schmid, MD PhD (Barts Cancer Institute Queen Mary University of London)